Company intelligence / Profile preview

Cajal Therapeutics

Seattle, Washington, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Cajal Therapeutics is a biotechnology company focused on discovering and developing novel therapies for neurodegenerative diseases. The company utilizes a proprietary platform that integrates human genetics, high-throughput functional genomics, and advanced imaging to identify and validate new drug targets. By mapping the genetic modifiers of disease progression in specific neuronal populations, Cajal aims to develop precision medicines for conditions like Alzheimer's and Parkinson's. The company was founded by industry veterans and is backed by leading life science investors.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Evotec

Beyond the preview

Go deeper on Cajal Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cajal Therapeutics.

Explore the full profile